ZC3H18

Across TCGA pan-cancer cohorts, ZC3H18 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ZC3H18 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZC3H18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZC3H18 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and SCLC are the cancer types where ZC3H18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.082	0.844	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.818	<.001	36	view →
SCLC	DFS	Median	All	0.210	0.636	.003	18	view →
LUSC	DFS	Median	II,III,IV	0.212	0.712	.001	18	view →
UCS	DFS	Median	IV	0.132	0.718	.002	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
COAD	OS	Median	All	0.285	0.711	.006	5	view →
ESCA	DFS	Median	II,III,IV	0.216	0.524	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ZC3H18–OV (OS)

Open the OV breakdown →